Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the First Affiliated Hospital of Guangzhou Medical University have entered into a collaborative agreement to contribute to the Guangzhou Lab’s project establishment and management. Guangzhou Lab is a cutting-edge research institution dedicated to the prevention and control of respiratory diseases, positioning itself as a pivotal technological force within China’s respiratory health domain.
The First Affiliated Hospital of Guangzhou Medical University is home to several renowned institutions, including the Guangzhou Institute of Respiratory Health, the National Clinical Research Center for Respiratory Disease, and the State Key Laboratory of Respiratory Disease. Under this new science research cooperation agreement, Cryofocus Bio and the hospital will jointly engage in the research and development of a liquid nitrogen ultra-low temperature freezing system and balloon freezing techniques for lung cancer ablation.
By pooling their resources and expertise, the two parties aim to advance the development of an innovative cryoballoon ablation product specifically designed for the treatment of peripheral lung cancer. This product will utilize the liquid nitrogen ultra-low temperature freezing system as its foundation, marking a significant step forward in the field of cryoablation treatments for respiratory diseases.- Flcube.com
